Medivir comments on the patent approval

The European Patent Office has approved Medivir’s patent application for combining fostrox and Lenvima to treat hepatocellular carcinoma (HCC) and liver metastases from other cancers. The patent runs until April 2041 and thus secures market exclusivity for a key part of the commercialisation phase. BioStock contacted Medivir’s CEO Jens Lindberg for a comment.

Read the full interview with Jens Lindberg at biostock.se:

https://www.biostock.se/en/2025/03/medivir-comments-on-the-patent-approval/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/